UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3' Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

Clinical cancer research, 2010-07, Vol.16 (14), p.3670-3683

2010

Volltextzugriff (PDF)

GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo

Clinical cancer research, 2012-07, Vol.18 (14), p.3901-3911

2012

Volltextzugriff (PDF)

Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes

PloS one, 2012-05, Vol.7 (5), p.e36402-e36402

2012

Volltextzugriff (PDF)

Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility

Cell, 2019-08, Vol.178 (4), p.949-963.e18

2019

Volltextzugriff (PDF)

GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer

Journal of medicinal chemistry, 2021-08, Vol.64 (16), p.11841-11856

2021

Volltextzugriff (PDF)

Abstract B36: Progesterone receptor signaling in estrogen receptor-positive breast cancer

Molecular cancer research, 2018-08, Vol.16 (8_Supplement), p.B36-B36

2018

Volltextzugriff (PDF)

Abstract 1004: Leveraging an expanding tool box for ER+ breast cancer: exploring breast cancer dependencies to support optimal therapeutic strategies

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.1004-1004

2019

Volltextzugriff (PDF)

RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy

Cancer discovery, 2022-01, Vol.12 (1), p.204-219

2022

Volltextzugriff (PDF)

GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway

Molecular cancer therapeutics, 2011-12, Vol.10 (12), p.2426-2436

2011

Volltextzugriff (PDF)

Abstract C201: A novel potent and selective inhibitor of PI3K/mTOR, GDC-0980, currently in phase I clinical trials

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.C201-C201

2009

Volltextzugriff (PDF)

Abstract P2-24-04: The ER antagonist giredestrant induces profound chromatin remodeling including activation of cis-regulatory elements bound by FOXA1 and GATA3 in HR+ breast cancer models

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.P2-P2-24-04

2023

Volltextzugriff (PDF)

Abstract 3406: GDC-9545: A pure antiestrogen clinical candidate that immobilizes the estrogen receptor and profoundly alters chromatin accessibility in vivo

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.3406-3406

2020

Volltextzugriff (PDF)

Maternal help‐seeking for child developmental concerns: Associations with socio‐demographic factors

Journal of paediatrics and child health, 2017-10, Vol.53 (10), p.963-969

2017

Volltextzugriff (PDF)

Abstract P2-11-05: ER pathway activity signature as a biomarker for endocrine agent GDC-9545

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P2-P2-11-05

2020

Volltextzugriff (PDF)

Abstract 5388: Triple-threat: Inavolisib and giredestrant combine with palbociclib to achieve sustained cell cycle arrest in ER-positive breast cancer models

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.5388-5388

2022

Volltextzugriff (PDF)

Abstract NG05: Not all “SERDs” are equal: Context-independent ER degradation and full ER antagonism define the next generation of ER therapeutics

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.NG05-NG05

2018

Volltextzugriff (PDF)

Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer

Science translational medicine, 2010-09, Vol.2 (48), p.48ra66

2010

Volltextzugriff (PDF)

Abstract 1648: Discovery and evolution of orally bioavailable selective estrogen receptor degraders for ER+ breast cancer: From GDC-0810 to GDC-0927

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1648-1648

2018

Volltextzugriff (PDF)

Abstract 546: GDC-0032 PI3K inhibitor enhances the efficacy of endocrine therapies in breast cancer cells by differentially regulating the expression of ER-targeted genes and increasing apoptosis

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.546-546

2013

Volltextzugriff (PDF)

Abstract 298: Mutant PIK3CA increases the expression of individual tubulin isoforms and promotes resistance to anti-mitotic chemotherapy drugs

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.298-298

2010

Volltextzugriff (PDF)

The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase

Genes & cancer, 2016-03, Vol.7 (3-4), p.73-85

2016

Volltextzugriff (PDF)

Abstract DDT02-01: Discovery of GDC-0032: A beta-sparing PI3K inhibitor active against PIK3CA mutant tumors

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.DDT02-01-DDT02-01

2013

Volltextzugriff (PDF)

Abstract C68: Endogenous expression of an oncogenic PI3K mutation leads to epithelial-mesenchymal transition (EMT) and invasiveness

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.C68-C68

2009

Volltextzugriff (PDF)

Antisense oligonucleotides to N-methyl- d-aspartate receptor subunits attenuate formalin-induced nociception in the rat

Brain research, 2002-03, Vol.930 (1), p.163-169

2002

Volltextzugriff (PDF)

Revisiting Phyllactinia species on Broussonetia spp. in China

Forest pathology = Journal de pathologie forestière = Zeitschrift für Forstpathologie, 2022-02, Vol.52 (1), p.n/a

2022

Volltextzugriff (PDF)

1 – 25 von 207

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(191)
Mit Volltextzugriff
(173)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(144)
Life Sciences & Biomedicine
(109)
Humans
(79)
Female
(47)
Male
(38)
Animals
(36)
Biological And Medical Sciences
(27)
Physical Sciences
(26)
Adult
(23)
Chemistry
(22)
Mice
(22)
Middle Aged
(22)
Medical Sciences
(20)
Infectious Diseases
(17)
Social Sciences
(14)
Technology
(14)
Aged
(13)
Oncology
(13)
Science & Technology - Other Topics
(13)
Gene Expression
(12)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3' Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo

Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes

Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility

GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer

Abstract B36: Progesterone receptor signaling in estrogen receptor-positive breast cancer

Abstract 1004: Leveraging an expanding tool box for ER+ breast cancer: exploring breast cancer dependencies to support optimal therapeutic strategies

RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy

GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway

Abstract C201: A novel potent and selective inhibitor of PI3K/mTOR, GDC-0980, currently in phase I clinical trials

Abstract P2-24-04: The ER antagonist giredestrant induces profound chromatin remodeling including activation of cis-regulatory elements bound by FOXA1 and GATA3 in HR+ breast cancer models

Abstract 3406: GDC-9545: A pure antiestrogen clinical candidate that immobilizes the estrogen receptor and profoundly alters chromatin accessibility in vivo

Maternal help‐seeking for child developmental concerns: Associations with socio‐demographic factors

Abstract P2-11-05: ER pathway activity signature as a biomarker for endocrine agent GDC-9545

Abstract 5388: Triple-threat: Inavolisib and giredestrant combine with palbociclib to achieve sustained cell cycle arrest in ER-positive breast cancer models

Abstract NG05: Not all “SERDs” are equal: Context-independent ER degradation and full ER antagonism define the next generation of ER therapeutics

Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer

Abstract 1648: Discovery and evolution of orally bioavailable selective estrogen receptor degraders for ER+ breast cancer: From GDC-0810 to GDC-0927

Abstract 546: GDC-0032 PI3K inhibitor enhances the efficacy of endocrine therapies in breast cancer cells by differentially regulating the expression of ER-targeted genes and increasing apoptosis

Abstract 298: Mutant PIK3CA increases the expression of individual tubulin isoforms and promotes resistance to anti-mitotic chemotherapy drugs

The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase

Abstract DDT02-01: Discovery of GDC-0032: A beta-sparing PI3K inhibitor active against PIK3CA mutant tumors

Abstract C68: Endogenous expression of an oncogenic PI3K mutation leads to epithelial-mesenchymal transition (EMT) and invasiveness

Antisense oligonucleotides to N-methyl- d-aspartate receptor subunits attenuate formalin-induced nociception in the rat

Revisiting Phyllactinia species on Broussonetia spp. in China

Suchergebnisse filtern